Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsHere we select some of the classical literature in the field of chimeric antigen receptor technology. It is hoped that these reviews and research articles will help you to understand CAR technology quickly and keep up with the cutting edge development of this area.
Nature reviews Clinical oncology 13, no. 6 (2016): 370-383.
Jackson, Hollie J., Sarwish Rafiq, and Renier J. Brentjens.
This Review discussed those ongoing clinical trials that tests CAR designs directed at novel targets involved in haematological and solid malignancies, and present strategies that can increase the antitumour efficacy and safety of CAR T‑cell therapy. Given the fast-moving nature of this field, this paper only discuss studies with direct translational application currently or soon‑to‑be tested in the clinical setting.
Trends in molecular medicine 18, no. 7 (2012): 377-384.
Gilham, David E., Reno Debets, Martin Pule, Robert E. Hawkins, and Hinrich Abken.
This article reviewed the current clinical application of CAR–T cells and relate clinical efficacy and safety of CAR–T cell trials to parameters considered critical for CAR engineering, classified as the three T’s of CAR–T cell manipulation, that is T cell subset, T cell processing, and T cell engineering.
Science translational medicine 7.280 (2015): 280ps7-280ps7.
June, Carl H., Stanley R. Riddell, and Ton N. Schumacher.
This review summrized pharmaceutical and biotechnology companies, their cell type and indications in the area of adoptive cell therapy for cancer, infection disease and graf -versus-host disease (GVHD).
Nature medicine 22.1 (2016): 26.
Klebanoff, Christopher A., Steven A. Rosenberg, and Nicholas P. Restifo.
This review offer the perspective on how expanding the use of genetically redirected T cells to treat the majority of patients with solid cancers will require major technical, manufacturing and regulatory innovations centered around the development of autologous gene therapies targeting private somatic mutations.
New England Journal of Medicine 375, no. 26 (2016): 2561-2569.
Brown, Christine E., Darya Alizadeh, Renate Starr, Lihong Weng, Jamie R. Wagner, Araceli Naranjo, Julie R. Ostberg et al.
This article reports a case of CAR-T therapy with positive results for the treatment of glioblastoma.
Blood 116, no. 20 (2010): 4099-4102.
Kochenderfer, James N., Wyndham H. Wilson, John E. Janik, Mark E. Dudley, Maryalice Stetler-Stevenson, Steven A. Feldman, Irina Maric et al.
This is the first reported case of effective clinical treatment with anti-CD19 CAR T cells.
Nature reviews Clinical oncology 10, no. 5 (2013): 267-276.
Kochenderfer, James N., and Steven A. Rosenberg.
This review summarized recent progress of anti-CD19 CAR-T technique for the treatment of B cell lymphoma.
Proceedings of the National Academy of Sciences 86, no. 24 (1989): 10024-10028.
Gross, Gideon, Tova Waks, and Zelig Eshhar.
This is the first paper that introduced the concept of chimeric antigen receptor
Cell 168, no. 4 (2017): 724-740.
Lim, W.A. and June, C.H.
This review summarized five major functional challenges for a therapeutic T cell and emerging new engineering solutions for addressing the functional challenges of anti-cancer T Cells.
Trends in Molecular Medicine (2017)
Chang, Ze Nan L., and Yvonne Y. Chen.
This review current understanding of the molecular properties of CARs, how this knowledge informs the rational design and characterization of novel receptors, the successes and shortcomings of CAR-T cells in the clinic, and emerging solutions for the continued improvement of CAR-T cell therapy
Nature reviews. Drug discovery 14.7 (2015): 499.
Van Der Stegen, Sjoukje JC, Mohamad Hamieh, and Michel Sadelain.
This review mainly talk about the combined activating and co-stimulatory domains of second-generation chimeric antigen receptors (CARs)
Nature 545.7655 (2017): 423-431.
Sadelain, Michel, Isabelle Rivière, and Stanley Riddell
This is a latest review of t cell engineering technique. Mainly talk about how to engineer and manufacture better T cells, what t cell to engineer and where to apply enginnered T cell.
Nature reviews Clinical oncology 13, no. 6 (2016): 370-383.
Jackson, Hollie J., Sarwish Rafiq, and Renier J. Brentjens.
This Review discussed those ongoing clinical trials that tests CAR designs directed at novel targets involved in haematological and solid malignancies, and present strategies that can increase the antitumour efficacy and safety of CAR T‑cell therapy. Given the fast-moving nature of this field, this paper only discuss studies with direct translational application currently or soon‑to‑be tested in the clinical setting.
Trends in molecular medicine 18, no. 7 (2012): 377-384.
Gilham, David E., Reno Debets, Martin Pule, Robert E. Hawkins, and Hinrich Abken.
This article reviewed the current clinical application of CAR–T cells and relate clinical efficacy and safety of CAR–T cell trials to parameters considered critical for CAR engineering, classified as the three T’s of CAR–T cell manipulation, that is T cell subset, T cell processing, and T cell engineering.
Science translational medicine 7.280 (2015): 280ps7-280ps7.
June, Carl H., Stanley R. Riddell, and Ton N. Schumacher.
This review summrized pharmaceutical and biotechnology companies, their cell type and indications in the area of adoptive cell therapy for cancer, infection disease and graf -versus-host disease (GVHD).
Nature medicine 22.1 (2016): 26.
Klebanoff, Christopher A., Steven A. Rosenberg, and Nicholas P. Restifo.
This review offer the perspective on how expanding the use of genetically redirected T cells to treat the majority of patients with solid cancers will require major technical, manufacturing and regulatory innovations centered around the development of autologous gene therapies targeting private somatic mutations.
New England Journal of Medicine 375, no. 26 (2016): 2561-2569.
Brown, Christine E., Darya Alizadeh, Renate Starr, Lihong Weng, Jamie R. Wagner, Araceli Naranjo, Julie R. Ostberg et al.
This article reports a case of CAR-T therapy with positive results for the treatment of glioblastoma.
Blood 116, no. 20 (2010): 4099-4102.
Kochenderfer, James N., Wyndham H. Wilson, John E. Janik, Mark E. Dudley, Maryalice Stetler-Stevenson, Steven A. Feldman, Irina Maric et al.
This is the first reported case of effective clinical treatment with anti-CD19 CAR T cells.
Nature reviews Clinical oncology 10, no. 5 (2013): 267-276.
Kochenderfer, James N., and Steven A. Rosenberg.
This review summarized recent progress of anti-CD19 CAR-T technique for the treatment of B cell lymphoma.
Proceedings of the National Academy of Sciences 86, no. 24 (1989): 10024-10028.
Gross, Gideon, Tova Waks, and Zelig Eshhar.
This is the first paper that introduced the concept of chimeric antigen receptor
Cell 168, no. 4 (2017): 724-740.
Lim, W.A. and June, C.H.
This review summarized five major functional challenges for a therapeutic T cell and emerging new engineering solutions for addressing the functional challenges of anti-cancer T Cells.
Trends in Molecular Medicine (2017)
Chang, Ze Nan L., and Yvonne Y. Chen.
This review current understanding of the molecular properties of CARs, how this knowledge informs the rational design and characterization of novel receptors, the successes and shortcomings of CAR-T cells in the clinic, and emerging solutions for the continued improvement of CAR-T cell therapy
Nature reviews. Drug discovery 14.7 (2015): 499.
Van Der Stegen, Sjoukje JC, Mohamad Hamieh, and Michel Sadelain.
This review mainly talk about the combined activating and co-stimulatory domains of second-generation chimeric antigen receptors (CARs)
Nature 545.7655 (2017): 423-431.
Sadelain, Michel, Isabelle Rivière, and Stanley Riddell
This is a latest review of t cell engineering technique. Mainly talk about how to engineer and manufacture better T cells, what t cell to engineer and where to apply enginnered T cell.
Nature reviews Clinical oncology 13, no. 6 (2016): 370-383.
Jackson, Hollie J., Sarwish Rafiq, and Renier J. Brentjens.
This Review discussed those ongoing clinical trials that tests CAR designs directed at novel targets involved in haematological and solid malignancies, and present strategies that can increase the antitumour efficacy and safety of CAR T‑cell therapy. Given the fast-moving nature of this field, this paper only discuss studies with direct translational application currently or soon‑to‑be tested in the clinical setting.
Trends in molecular medicine 18, no. 7 (2012): 377-384.
Gilham, David E., Reno Debets, Martin Pule, Robert E. Hawkins, and Hinrich Abken.
This article reviewed the current clinical application of CAR–T cells and relate clinical efficacy and safety of CAR–T cell trials to parameters considered critical for CAR engineering, classified as the three T’s of CAR–T cell manipulation, that is T cell subset, T cell processing, and T cell engineering.
Science translational medicine 7.280 (2015): 280ps7-280ps7.
June, Carl H., Stanley R. Riddell, and Ton N. Schumacher.
This review summrized pharmaceutical and biotechnology companies, their cell type and indications in the area of adoptive cell therapy for cancer, infection disease and graf -versus-host disease (GVHD).
Nature medicine 22.1 (2016): 26.
Klebanoff, Christopher A., Steven A. Rosenberg, and Nicholas P. Restifo.
This review offer the perspective on how expanding the use of genetically redirected T cells to treat the majority of patients with solid cancers will require major technical, manufacturing and regulatory innovations centered around the development of autologous gene therapies targeting private somatic mutations.
New England Journal of Medicine 375, no. 26 (2016): 2561-2569.
Brown, Christine E., Darya Alizadeh, Renate Starr, Lihong Weng, Jamie R. Wagner, Araceli Naranjo, Julie R. Ostberg et al.
This article reports a case of CAR-T therapy with positive results for the treatment of glioblastoma.
Blood 116, no. 20 (2010): 4099-4102.
Kochenderfer, James N., Wyndham H. Wilson, John E. Janik, Mark E. Dudley, Maryalice Stetler-Stevenson, Steven A. Feldman, Irina Maric et al.
This is the first reported case of effective clinical treatment with anti-CD19 CAR T cells.
Nature reviews Clinical oncology 10, no. 5 (2013): 267-276.
Kochenderfer, James N., and Steven A. Rosenberg.
This review summarized recent progress of anti-CD19 CAR-T technique for the treatment of B cell lymphoma.
Proceedings of the National Academy of Sciences 86, no. 24 (1989): 10024-10028.
Gross, Gideon, Tova Waks, and Zelig Eshhar.
This is the first paper that introduced the concept of chimeric antigen receptor
Cell 168, no. 4 (2017): 724-740.
Lim, W.A. and June, C.H.
This review summarized five major functional challenges for a therapeutic T cell and emerging new engineering solutions for addressing the functional challenges of anti-cancer T Cells.
Trends in Molecular Medicine (2017)
Chang, Ze Nan L., and Yvonne Y. Chen.
This review current understanding of the molecular properties of CARs, how this knowledge informs the rational design and characterization of novel receptors, the successes and shortcomings of CAR-T cells in the clinic, and emerging solutions for the continued improvement of CAR-T cell therapy
Nature reviews. Drug discovery 14.7 (2015): 499.
Van Der Stegen, Sjoukje JC, Mohamad Hamieh, and Michel Sadelain.
This review mainly talk about the combined activating and co-stimulatory domains of second-generation chimeric antigen receptors (CARs)
Nature 545.7655 (2017): 423-431.
Sadelain, Michel, Isabelle Rivière, and Stanley Riddell
This is a latest review of t cell engineering technique. Mainly talk about how to engineer and manufacture better T cells, what t cell to engineer and where to apply enginnered T cell.
Nature reviews Clinical oncology 13, no. 6 (2016): 370-383.
Jackson, Hollie J., Sarwish Rafiq, and Renier J. Brentjens.
This Review discussed those ongoing clinical trials that tests CAR designs directed at novel targets involved in haematological and solid malignancies, and present strategies that can increase the antitumour efficacy and safety of CAR T‑cell therapy. Given the fast-moving nature of this field, this paper only discuss studies with direct translational application currently or soon‑to‑be tested in the clinical setting.
Trends in molecular medicine 18, no. 7 (2012): 377-384.
Gilham, David E., Reno Debets, Martin Pule, Robert E. Hawkins, and Hinrich Abken.
This article reviewed the current clinical application of CAR–T cells and relate clinical efficacy and safety of CAR–T cell trials to parameters considered critical for CAR engineering, classified as the three T’s of CAR–T cell manipulation, that is T cell subset, T cell processing, and T cell engineering.
Science translational medicine 7.280 (2015): 280ps7-280ps7.
June, Carl H., Stanley R. Riddell, and Ton N. Schumacher.
This review summrized pharmaceutical and biotechnology companies, their cell type and indications in the area of adoptive cell therapy for cancer, infection disease and graf -versus-host disease (GVHD).
Nature medicine 22.1 (2016): 26.
Klebanoff, Christopher A., Steven A. Rosenberg, and Nicholas P. Restifo.
This review offer the perspective on how expanding the use of genetically redirected T cells to treat the majority of patients with solid cancers will require major technical, manufacturing and regulatory innovations centered around the development of autologous gene therapies targeting private somatic mutations.
New England Journal of Medicine 375, no. 26 (2016): 2561-2569.
Brown, Christine E., Darya Alizadeh, Renate Starr, Lihong Weng, Jamie R. Wagner, Araceli Naranjo, Julie R. Ostberg et al.
This article reports a case of CAR-T therapy with positive results for the treatment of glioblastoma.
Blood 116, no. 20 (2010): 4099-4102.
Kochenderfer, James N., Wyndham H. Wilson, John E. Janik, Mark E. Dudley, Maryalice Stetler-Stevenson, Steven A. Feldman, Irina Maric et al.
This is the first reported case of effective clinical treatment with anti-CD19 CAR T cells.
Nature reviews Clinical oncology 10, no. 5 (2013): 267-276.
Kochenderfer, James N., and Steven A. Rosenberg.
This review summarized recent progress of anti-CD19 CAR-T technique for the treatment of B cell lymphoma.
Proceedings of the National Academy of Sciences 86, no. 24 (1989): 10024-10028.
Gross, Gideon, Tova Waks, and Zelig Eshhar.
This is the first paper that introduced the concept of chimeric antigen receptor
Cell 168, no. 4 (2017): 724-740.
Lim, W.A. and June, C.H.
This review summarized five major functional challenges for a therapeutic T cell and emerging new engineering solutions for addressing the functional challenges of anti-cancer T Cells.
Trends in Molecular Medicine (2017)
Chang, Ze Nan L., and Yvonne Y. Chen.
This review current understanding of the molecular properties of CARs, how this knowledge informs the rational design and characterization of novel receptors, the successes and shortcomings of CAR-T cells in the clinic, and emerging solutions for the continued improvement of CAR-T cell therapy
Nature reviews. Drug discovery 14.7 (2015): 499.
Van Der Stegen, Sjoukje JC, Mohamad Hamieh, and Michel Sadelain.
This review mainly talk about the combined activating and co-stimulatory domains of second-generation chimeric antigen receptors (CARs)
Nature 545.7655 (2017): 423-431.
Sadelain, Michel, Isabelle Rivière, and Stanley Riddell
This is a latest review of t cell engineering technique. Mainly talk about how to engineer and manufacture better T cells, what t cell to engineer and where to apply enginnered T cell.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
